JY
IOVA icon

Jeff Yass’s Iovance Biotherapeutics IOVA Stock Holding History

Jeff Yass’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.1M Sell
2,656,740
-340,003
-11% -$1.29M ﹤0.01% 3239
2026
Q1 		$10.5M Sell
2,996,743
-1,951,871
-39% -$6.24M ﹤0.01% 3040
2025
Q4 		$13.5M Buy
4,948,614
+1,642,098
+50% +$3.8M ﹤0.01% 2674
2025
Q3 		$7.18M Buy
3,306,516
+1,235,044
+60% +$2.92M ﹤0.01% 3522
2025
Q2 		$3.56M Buy
2,071,472
+269,279
+15% +$670K ﹤0.01% 4630
2025
Q1 		$6M Sell
1,802,193
-860,502
-32% -$4.44M ﹤0.01% 3311
2024
Q4 		$19.7M Buy
2,662,695
+1,248,778
+88% +$11.6M ﹤0.01% 1873
2024
Q3 		$13.3M Buy
1,413,917
+422,268
+43% +$4M ﹤0.01% 2259
2024
Q2 		$7.95M Sell
991,649
-825,351
-45% -$8.84M ﹤0.01% 2779
2024
Q1 		$26.9M Buy
1,817,000
+218,070
+14% +$2.54M ﹤0.01% 1499
2023
Q4 		$13M Buy
1,598,930
+353,893
+28% +$1.85M ﹤0.01% 2308
2023
Q3 		$5.66M Buy
1,245,037
+881,054
+242% +$5.75M ﹤0.01% 3325
2023
Q2 		$2.56M Sell
363,983
-245,192
-40% -$1.75M ﹤0.01% 4648
2023
Q1 		$3.72M Buy
609,175
+417,427
+218% +$2.88M ﹤0.01% 3904
2022
Q4 		$1.23M Sell
191,748
-119,875
-38% -$936K ﹤0.01% 5744
2022
Q3 		$2.98M Buy
311,623
+198,343
+175% +$2.29M ﹤0.01% 4100
2022
Q2 		$1.25M Sell
113,280
-304,873
-73% -$4M ﹤0.01% 5973
2022
Q1 		$6.96M Sell
418,153
-276,847
-40% -$4.28M ﹤0.01% 3093
2021
Q4 		$13.3M Buy
695,000
+73,961
+12% +$1.63M ﹤0.01% 2333
2021
Q3 		$15.3M Sell
621,039
-194,809
-24% -$4.59M ﹤0.01% 2284
2021
Q2 		$21.2M Buy
815,848
+684,759
+522% +$17.8M ﹤0.01% 1948
2021
Q1 		$4.15M Buy
131,089
+58,180
+80% +$2.41M ﹤0.01% 4270
2020
Q4 		$3.38M Sell
72,909
-682,028
-90% -$27.1M ﹤0.01% 4105
2020
Q3 		$24.9M Buy
754,937
+254,452
+51% +$7.8M ﹤0.01% 1307
2020
Q2 		$13.7M Sell
500,485
-161,876
-24% -$5.32M ﹤0.01% 1790
2020
Q1 		$19.8M Buy
+662,361
New +$17.6M 0.01% 1170
2019
Q4 		– Sell
-126,084
Closed -$2.87M – 10145
2019
Q3 		$2.29M Buy
126,084
+49,851
+65% +$1.1M ﹤0.01% 3924
2019
Q2 		$1.87M Buy
+76,233
New +$1.15M ﹤0.01% 4304
2018
Q1 		– Sell
-50,187
Closed -$760K – 9719
2017
Q4 		$401K Sell
50,187
-652,886
-93% -$5.24M ﹤0.01% 7051
2017
Q3 		$5.45M Buy
703,073
+610,974
+663% +$3.87M ﹤0.01% 2391
2017
Q2 		$677K Buy
+92,099
New +$585K ﹤0.01% 6043
2017
Q1 		– Sell
-126,015
Closed -$924K – 9422
2016
Q4 		$876K Buy
+126,015
New +$867K ﹤0.01% 5812
2016
Q1 		– Sell
-12,364
Closed -$67.7K – 9318
2015
Q4 		$95K Sell
12,364
-21,870
-64% -$152K ﹤0.01% 8903
2015
Q3 		$197K Buy
34,234
+2,997
+10% +$23.3K ﹤0.01% 8718
2015
Q2 		$286K Sell
31,237
-37,308
-54% -$416K ﹤0.01% 8613
2015
Q1 		$830K Buy
+68,545
New +$772K ﹤0.01% 6124

Other funds holding IOVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Jeff Yass's IOVA Position: Q2 2026 in Review

Jeff Yass reduced its Iovance Biotherapeutics (IOVA) stake by 11% in Q2 2026, selling an estimated $1.29M and leaving 2,656,740 shares worth $11.1M. The position accounts for ﹤0.01% of the portfolio, ranked #3239.

Jeff Yass first reported a position in IOVA in Q1 2015 and has held it in 36 quarters since. The position peaked at $26.9M in Q1 2024. 290 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

  • Jeff Yass held 2,656,740 shares of Iovance Biotherapeutics worth $11.1M as of Q2 2026.
  • Jeff Yass sold 340,003 Iovance Biotherapeutics shares in Q2 2026, an estimated $1.29M.
  • Iovance Biotherapeutics made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #3239 holding.
  • Jeff Yass first reported a position in Iovance Biotherapeutics in Q1 2015 and has held it in 36 quarters since.
  • Jeff Yass's Iovance Biotherapeutics position peaked at $26.9M in Q1 2024.
  • 290 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.